Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Tegobuvir

Catalog No: tcsc0672

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Specifications

CAS No:
1000787-75-6

Formula:
$C_{25}H_{14}F_7N_5$

Pathway:
Anti-infection

Target:
HCV

Purity / Grade:
>98%

Solubility:
10 mM in DMSO

Alternative Names:
GS 333126;GS-9190

Observed Molecular Weight:
517.4

Product Description

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Tegobuvir is a specific, covalent inhibitor of the **HCV NS5B polymerase**.

In Vitro: Tegobuvir rapidly increases the proportion of replicons with the Y448H mutation in a dose-dependent manner. After 3 days of treatment, 1.2%, 6.8%, and > 50% of the replicon population expresses Y448H with the use of Tegobuvir at 1, 10, and 20 times its 50% effective concentration, respectively[1]. Tegobuvir exerts anti-HCV activity utilizing a unique chemical activation and subsequent direct interaction with the NS5B protein. Treatment of HCV subgenomic replicon cells with Tegobuvir results in a modified form of NS5B with a distinctly altered mobility on a SDS-PAGE gel[2]. Tegobuvir is potent in GT1a and 1b with mean EC_{50}s of 19.8 and 1.5 nM respectively. For genotype 3a, 4a, and 6a Con chimeras, tegobuvir EC_{50}s are all greater than 100 nM. The F445C NS5B mutations in GT3a, 4a, and 6a chimeric replicons restore tegobuvir potency to EC_{50} levels comparable to GT1a[3].